Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Purpose To assess and compare the therapeutic efficacy of Liraglutide, Tirzepatide, and Retatrutide in treating diabetic kidney disease (DKD) in db/db mice. Methods Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks. Subsequently, we assessed the effectiveness of these three drugs in controlling blood glucose levels, reducing weight, and improving serum biochemical indicators and DKD. Additionally, we measured and compared the renal inflammation and fibrosis indexes. Meanwhile, the content of intestinal metabolite butyrate was compared to reflect the regulatory effects of these three drugs on gut microbiota. Results Retatrutide demonstrated superior effectiveness in reducing weight and improving renal function in db/db mice compared to Liraglutide and Tirzepatide. Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice. Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs. Unfortunately, despite its ability to lower blood glucose levels, Retatrutide did not outperform the other two drugs…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings strongly indicate that all three drugs are effective in reducing food intake and promoting weight loss, with retatrutide demonstrating the most significant impact.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“Regarding HbA1c levels, retatrutide showed lower levels than those in the db/db group.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“At the end of the experiment, the weight of mice in the db/db + Reta group decreased, and at 10 weeks, db/db + Reta group mice had the lowest levels of body weight and food intake, followed by db/db + Tirz group and db/db + Lira group, with a statistically significant difference.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“Finally, after immunohistochemical analysis, retatrutide exhibited lower expression levels of inflammatory and fibrotic mediators compared to tirzepatide and liraglutide, highlighting its potential in the treatment of diabetic kidney disease.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
In the citing paper
“At 8 weeks of age, the mice were randomly divided into 5 groups (each n = 6): db/m, db/db, db/db + Lira, db/db + Tirz, and db/db + Reta.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [41]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Despite the current clinical use of renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose cotransporter 2 inhibitors (SGLT2is) [2, 3] in the treatment of DKD, progressive decline in renal function persists among numerous patients.”
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Additionally, another clinical trial involving obese or overweight patients revealed that Tir-zepatide effectively reduced body weight and improved cardiorenal risk factors, encompassing blood glucose levels, blood pressure, glycated hemoglobin, and albumi-nuria [17].”
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423 · cited 1×
“However, clinical studies have shown that mild to moderate gastrointestinal symptoms, such as nausea, vomiting and diarrhea, are still the most common adverse reactions of these two drugs, and their safety pro fi le is consistent with GLP-1RAs [16, 36], making it a potential treatment option for DKD.”
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406 · cited 1×
“Moreover, it has been proven to reduce body weight and suppress appetite, delay gastrointestinal peristalsis, and stimulate insulin secretion [13 – 15].”
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“However, the ef fi cacy of GLP-1RAs alone is hindered by dose-dependent gastrointestinal adverse events [5, 6], and often leads to poor tolerance or inadequate ef fi cacy in patients with type 2 diabetes mellitus (T2DM) [7, 8].”
Trajectories of kidney function in diabetes: a clinicopathological update
Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., Hara, A., Furuichi, K., & Wada, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00462-y · Cited by 346 · cited 1×
“Diabetic kidney disease (DKD) is a prevalent complication of diabetes mellitus (DM), affecting around 40% of individuals with diabetes, and it stands as the primary cause of end-stage renal disease (ESRD) worldwide [1].”
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 1×
“In previous clinical trials exploring cotadutide, a GLP-1/GCG dual agonist, reductions in both HbA1c levels and body weight were observed [34].”
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316 · cited 1×
“Furthermore, it has exhibited superiority over Tirzepatide in reducing body weight in obese mice [19].”
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306 · cited 1×
“Tirzepatide and GLP-1/GIP/GCG trireceptor agonizts has shown favorable outcomes in improving DKD in several studies [24, 25].”
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255 · cited 1×
“Glucagon-like peptide-1 receptor agonizts (GLP-1RAs), such as Lir-aglutide and Semaglutide [4], have recently demonstrated in improving renal and cardiovascular outcomes for patients with DKD.”
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240 · cited 2×
“Consequently, such single-target drugs have failed to achieve the anticipated outcomes in the treatment of T2DM [8].”
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235 · cited 1×
“Therefore, Various combinations of GLP-1RAs and other peptide-based hormonal agents are being investigated to achieve additive or synergistic effects through complementary mechanisms, thereby enhancing weight loss and diabetes treatment [9 – 11].”
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202 · cited 1×
“Moreover, Retatrutide(Synonyms: LY3437943), a GLP-1/GIP/GCG triple receptor agonist, has been shown to improve blood glucose and body weight in T2DM patients [18].”
Sodium butyrate supplementation ameliorates diabetic inflammation in db/db mice
Xu, Y., Gao, C., Guo, H., Zhang, W., Huang, W. G., Tang, S., Gan, W.-J., Xu, Y., Zhou, H., & Zhu, Q. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0137 · Cited by 158 · cited 1×
“The gut metabolite butyrate has shown promising effects in ameliorating DKD by reducing in fl ammation, oxidative stress, fi brosis, cell scorching, and DNA damage in various animal models [29 – 31].”
Self-citationSodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC
Dong, W., Jia, Y., Liu, X., Zhang, H., Li, T., Huang, W., Chen, X., Wang, F., Sun, W., & Wu, H. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0322 · Cited by 155
Khan, S., & Jena, G. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.08.010 · Cited by 141 · cited 1×
“The gut metabolite butyrate has shown promising effects in ameliorating DKD by reducing in fl ammation, oxidative stress, fi brosis, cell scorching, and DNA damage in various animal models [29 – 31].”
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123 · cited 1×
“However, the ef fi cacy of GLP-1RAs alone is hindered by dose-dependent gastrointestinal adverse events [5, 6], and often leads to poor tolerance or inadequate ef fi cacy in patients with type 2 diabetes mellitus (T2DM) [7, 8].”
GLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 115 · cited 1×
“GLP-1RAs exhibit a renoprotective effect by decreasing UAER and decelerating the estimated glomerular fi ltration rate (eGFR) among individuals with T2DM [21].”
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115 · cited 1×
“Owing to their distinct advantages and mechanisms of action, incretin agonizts have emerged as a prominent fi eld of study in diabetes treatment research [22].”
Parker, J. A., McCullough, K. A., Field, B. C. T., Minnion, J. S., Martin, N. M., Ghatei, M. A., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.227 · Cited by 111 · cited 1×
“This may be because GCG may act as an anorexic hormone to promote energy expenditure and weight loss [26], but at the same time it can also stimulate hepatic gluconeogenesis, leading to increased blood glucose levels [27].”
Alba, M., Yee, J., Frustaci, M. E., Samtani, M. N., & Fleck, P. (2021) · Clinical Obesity · doi:10.1111/cob.12432 · Cited by 100
Christensen, M. B., Calanna, S., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3644 · Cited by 99
Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice
Liu, Q., Cai, B.-Y., Zhu, L.-X., Xin, X., Wang, X., An, Z.-M., Li, S., Hu, Y.-Y., & Feng, Q. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118457 · Cited by 91 · cited 1×
“Additionally, GLP-1RAs have been found to alleviate nonalcoholic fatty liver disease in db/db mice through the regulation of gut microbiota [33].”
Glucagon as a target for the treatment of Type 2 diabetes
Sloop, K. W., Michael, M. D., & Moyers, J. S. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.593 · Cited by 63 · cited 1×
“This may be because GCG may act as an anorexic hormone to promote energy expenditure and weight loss [26], but at the same time it can also stimulate hepatic gluconeogenesis, leading to increased blood glucose levels [27].”
Charpentier, J., Briand, F., Lelouvier, B., Servant, F., Azalbert, V., Puel, A., Christensen, J. E., Waget, A., Branchereau, M., Garret, C., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01657-8 · Cited by 51 · cited 1×
“Furthermore, studies have demonstrated that GLP-1RAs target the gut microbiota and intestinal immune system to regulate insulin secretion [32].”
Mochiki, E., Suzuki, H., Takenoshita, S., Nagamachi, Y., Kuwano, H., Mizumoto, A., & Itoh, Z. (1998) · Journal of Gastroenterology · doi:10.1007/s005350050184 · Cited by 38
Song, G., Pacini, G., Ahrén, B., & D’Argenio, D. Z. (2017) · Peptides · doi:10.1016/j.peptides.2016.12.012 · Cited by 33 · cited 1×
“Moreover, it has been proven to reduce body weight and suppress appetite, delay gastrointestinal peristalsis, and stimulate insulin secretion [13 – 15].”
Han, Y. Z., Zheng, H., Du, B. X., Zhang, Y., Zhu, X. Y., Li, J., Wang, Y., & Liu, W. J. (2023) · Journal of Diabetes Research · doi:10.1155/2023/8871677 · Cited by 25 · cited 1×
“…mice were intraperitoneally injected with Tirzepatide; db/db + Reta: db/db mice were intraperitoneally injected with Retatrutide Imbalances in gut microbiota and its metabolites have been implicated in the promotion of DKD development through their effects on immunity and oxidative stress [28].”
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24 · cited 1×
“However, the ef fi cacy of GLP-1RAs alone is hindered by dose-dependent gastrointestinal adverse events [5, 6], and often leads to poor tolerance or inadequate ef fi cacy in patients with type 2 diabetes mellitus (T2DM) [7, 8].”
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Cui, J., Shang, A., Wang, W., & Chen, W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118339 · Cited by 20 · cited 1×
“Tirzepatide and GLP-1/GIP/GCG trireceptor agonizts has shown favorable outcomes in improving DKD in several studies [24, 25].”
Multi-functional Chimeric Peptides: The More the Merrier
Singh, A., & Srivastava, V. (2019) · Protein & Peptide Letters · doi:10.2174/0929866525666181120090857 · Cited by 8 · cited 1×
“Therefore, Various combinations of GLP-1RAs and other peptide-based hormonal agents are being investigated to achieve additive or synergistic effects through complementary mechanisms, thereby enhancing weight loss and diabetes treatment [9 – 11].”
GLP‐1‐based diabetes therapies; trial by media
Hitman, G. A., Leslie, R. D., & Holt, R. I. G. (2013) · Diabetic Medicine · doi:10.1111/dme.12299 · Cited by 6 · cited 1×
“Nevertheless, recent reports have found that it is dif fi cult to completely prevent DKD from progressing to ESRD if only the GLP-1 receptor is activated, while increasing gastrointestinal adverse reactions such as nausea and vomiting [23].”
Cited by
Ullah, A., & Shen, B. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118065 · Cited by 48
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025) · Biomolecules · doi:10.3390/biom15060796 · Cited by 29
“Another study by Ma et al. aimed to compare the effects of retatrutide, liraglutide, and tirzepatide on diabetic kidney disease in db/db mice [41].”
Vekić, J., Zeljković, A., Maggio, V., Rizzo, M., & Medenica, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01828-2 · Cited by 11
“In preclinical studies, retatrutide was recently shown as the most effective incretin-based agent in db/db mouse model of diabetic kidney disease [97].”
Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease
Ma, J., Tao, M., Zhang, W., Zhou, L., Zhang, H., Li, F., Zhang, H., Yao, D., Lu, W., & Wang, M. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1715024 · Cited by 13
“Both db/m and db/db mice were administered identical saline volumes through intraperitoneal injections during the identical timeframe (Yang et al., 2024a; Ma et al., 2025).”
Self-citationObesity as a modifiable risk factor in patients with chronic kidney disease
Morales, E., Jenssen, T. G., Bevc, S., Miglinas, M., Martin, W. P., Theodorakopoulou, M. P., Jørgensen, M. B., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf231 · Cited by 10
Metadata
- Authors
- Ma, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W.
- Affiliations
- Huaian First People’s Hospital (CN)
- Corresponding author
- Wang, Min
- Lu, Weiping
- Venue
- Endocrine
- Published
- 2024-08-30
- Volume
- 87
- Issue
- 1
- Pages
- 159-169
- ISSN
- 0969-711X (ISSN-L)
- 1559-0100
- OpenAlex
- W4402061935
- Cited by
- 21
- References
- 36
- Citations by year
- 2026: 10 · 2025: 11
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Endocrine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Development Fund of the Affiliated Hospital of Xuzhou Medical University (No. XYFY2021031.)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, liraglutide, tirzepatide, retatrutide, db/db mice, renal fibrosis, renal inflammation, butyrate, gut microbiota, intestinal metabolites, glycemic control, weight loss, lipid metabolism, inflammatory cytokines, NLRP3 inflammasome, caspase-1, fibronectin, type 2 diabetes
- MeSH terms
- Gastrointestinal Microbiome, Liraglutide, Tirzepatide, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Fatty Acids, Hypoglycemic Agents, Kidney, Male, Mice, Inbred C57BL, Peptides, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.